Mortality Risk Reduction: Ozempic, a diabetes drug, has been found to cut the risk of death in patients with type 2 diabetes and chronic kidney disease by 20%.
Cardiovascular Benefits: The drug also lowered the risk of cardiovascular-related deaths by 29% and major heart complications by 18%.
Kidney Disease Progression: Ozempic slowed the progression of kidney disease, with recipients being 24% less likely to experience major kidney disease events, including kidney failure and death due to kidney complications.
Semaglutide's Mechanism: The exact mechanism behind semaglutide's kidney benefits is still unclear, but it may involve reducing inflammation in the kidneys.
Broader Implications: The study's findings could potentially broaden the eligibility criteria for Ozempic injections and offer additional benefits over other classes of drugs approved to treat this population.